SUPN · Supernus Pharmaceuticals, Inc. · Webcasts, Transcripts & Audio
$42.18
-0.86 (-2.00%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$2.48B
Shares
58.13M
Volume · Oct 1
424.65K
Avg daily vol (3M)
788.96K
Supernus Pharmaceuticals, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Supernus Pharmaceuticals, Inc. (SUPN), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲19.5%
$177.35M
$1.75M
'22 Q3
22-11-08
▲5.2%
$167.33M
$25.48M
'22 Q4
23-02-28
▲0.8%
$153.76M
$16.95M
'23 Q1
23-05-09
▼20.3%
$135.56M
−$831,000
'23 Q2
23-07-24
▼13.2%
$153.88M
−$15.98M
'23 Q3
23-10-25
▼1.8%
$164.31M
$1.18M
'23 Q4
24-02-27
▼6.6%
$143.64M
$124,000
'24 Q1
24-04-24
▲24.2%
$168.32M
$19.92M
'24 Q2
24-08-06
▲14.2%
$175.69M
$38.50M
'24 Q3
24-10-21
▲6%
$174.16M
$15.33M
'24 Q4
25-02-11
▲4.3%
$149.82M
−$11.83M
'25 Q1
25-04-23
▼1.7%
$165.45M
$22.50M
'25 Q2
25-07-22
▲9.3%
$192.10M
−$45.12M
'25 Q3
25-10-21
▲21.5%
$211.57M
−$4.11M
'25 Q4
26-02-24
▲38.6%
$207.71M
−$2.29M
'26 Q1
26-05-05
LATEST
▲32.4%
$219.06M
−$58.37M
'26 Q2
26-08-03
Conference
Investor event
2026-08-03
Supernus Pharmaceuticals, Inc. (SUPN) August 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-03
Supernus Pharmaceuticals, Inc. (SUPN) Q2 2026 Earnings Call
Revenue
$219.06M
▲ 32.4% YoY Diluted EPS
$-1.01
▼ 352.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
Supernus Pharmaceuticals, Inc. (SUPN) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-05
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call Transcript
Confident tone
Onapto/Oxtellar XR rebound and second supplier
Quillivant/Kelbree ADHD franchise
Zurzuvae collaboration growth
Revenue
$207.71M
▲ 38.6% YoY Diluted EPS
$-0.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-24
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2025 Earnings Call Transcript
Confident tone
Growth products portfolio
ONAPCO launch and supply
Calvary performance and gross-to-net
Revenue
$211.57M*
▲ 21.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-21
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2025 Earnings Call Transcript
Confident tone
Onapgo launch and supply constraints
Zurzuvae collaboration and women's health
Apomorphine differentiation vs. competitors
Revenue
$192.10M
▲ 9.3% YoY Diluted EPS
$-0.80
▼ 215.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-22
Supernus Pharmaceuticals, Inc. (SUPN) Q2 2025 Earnings Call Transcript
Confident tone
Qelbree growth driver
Financial performance and operating expenses
Sage Therapeutics acquisition and ZURZUVAE
Revenue
$165.45M
▼ 1.7% YoY Diluted EPS
$0.40
▲ 11.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-23
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2025 Earnings Call Transcript
Confident tone
Qelbree growth
Pipeline advancement (SPN-820, SPN-443)
ONAPGO launch
Revenue
$149.82M
▲ 4.3% YoY Diluted EPS
$-0.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-11
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2024 Earnings Call Transcript
Confident tone
Qelbree growth and label update
ONAPGO launch
Corporate development and financial strength
Revenue
$174.16M*
▲ 6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-21
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2024 Earnings Call Transcript
Confident tone
Qelbree Growth
GOCOVRI Recovery
SPN-817 for Treatment-Resistant Seizures
Revenue
$175.69M
▲ 14.2% YoY Diluted EPS
$0.69
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Supernus Pharmaceuticals, Inc. (SUPN) Q2 2024 Earnings Call Transcript
Confident tone
Qelbree growth and gross-to-net
SPN-443 ADHD candidate
Legacy product erosion
Revenue
$168.32M
▲ 24.2% YoY Diluted EPS
$0.36
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-24
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2024 Earnings Call Transcript
Positive tone
Qelbree growth and net sales
Legacy product erosion (Trokendi XR / Oxtellar XR)
Pipeline catalysts (SPN-820, SPN-817, SPN-443)
Revenue
$143.64M
▼ 6.6% YoY Diluted EPS
$0.00
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2023 Earnings Call Transcript
Confident tone
Qelbree growth
Trokendi XR / Oxtellar XR legacy erosion
ADHD market dynamics
Revenue
$164.31M*
▼ 1.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-25
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2023 Earnings Call Transcript
Revenue
$153.88M
▼ 13.2% YoY Diluted EPS
$-0.29
▼ 1066.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-07-24
Supernus Pharmaceuticals, Inc. (SUPN) Q2 2023 Earnings Call Transcript
Revenue
$135.56M
▼ 20.3% YoY Diluted EPS
$-0.02
▼ 114.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2023 Earnings Call Transcript
Revenue
$153.76M
▲ 0.8% YoY Diluted EPS
$0.29
▼ 32.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2022 Earnings Call Transcript
Revenue
$167.33M*
▲ 5.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2022 Earnings Call Transcript
Revenue
$177.35M
▲ 19.5% YoY Diluted EPS
$0.03
▼ 92.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Supernus Pharmaceuticals, Inc. (SUPN) Q2 2022 Earnings Call Transcript
Revenue
$170.05M
▲ 20.3% YoY Diluted EPS
$0.14
▼ 67.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2022 Earnings Call Transcript
Revenue
$152.51M
▲ 16.5% YoY Diluted EPS
$0.43
▲ 290.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2021 Earnings Call Transcript
Revenue
$159.05M*
▲ 10.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-28
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2021 Earnings Call Transcript
Revenue
$148.46M
▼ 4.3% YoY Diluted EPS
$0.40
▼ 45.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
Supernus Pharmaceuticals, Inc. (SUPN) Q2 2021 Earnings Call Transcript
Revenue
$141.33M
▲ 11.5% YoY Diluted EPS
$0.43
▼ 33.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2021 Earnings Call Transcript
Revenue
$130.93M
▲ 37.9% YoY Diluted EPS
$0.11
▼ 72.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-24
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2020 Earnings Call Transcript
Revenue
$143.56M*
▲ 42.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2020 Earnings Call Transcript
Revenue
$155.13M
▲ 51.9% YoY Diluted EPS
$0.74
▲ 37% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-11
Supernus Pharmaceuticals, Inc. (SUPN) Q2 2020 Earnings Call Transcript
Revenue
$126.73M
▲ 21% YoY Diluted EPS
$0.65
▲ 6.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2020 Earnings Call
Revenue
$94.98M
▲ 11.1% YoY Diluted EPS
$0.40
▲ 17.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-27
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2019 Earnings Call
Revenue
$100.45M
▼ 13.4% YoY Diluted EPS
$0.62
▲ 29.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–29 of 29 webcasts
Key facts
CIK
1356576
CUSIP
868459108
13F (30d)
12 filings
10 filers
Visit website
Investor relations